8 recruiting, 6 unknown, 5 not yet recruiting, 4 completed. 29 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Recruiting 8, Unknown 6, Not yet recruiting 5, Completed 4, Terminated 4, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 2 | Completed 2 |
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) Trilaciclib, Eribulin - Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-11-04 | 2025-12-01 |
| Trilaciclib Combined With Immunochemotherapy for R/M HNSCC Trilaciclib - Head & Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 32 | 2026-06-01 | 2026-07-01 |
| Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Trilaciclib and Sacituzumab Tirumotecan - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 49 | 2025-12-08 | 2026-04-14 |
| Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC Trilaciclib + Cisplatin - Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Hunan Cancer Hospital | 30 | 2024-12-30 | 2024-12-31 |
| Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trilaciclib - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | Not yet recruiting | Shandong Cancer Hospital and Institute | 30 | 2024-12-15 | 2024-12-03 |
| Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma Trilaciclib, Pirarubicin, Lobaplatin - Osteosarcoma | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-11-13 | 2024-12-03 |
| A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib Chemotherapy, Trilaciclib Injection [Cosela] - Ewing Sarcoma, Myelosuppression | Phase 2 | Recruiting | Fudan University | 22 | 2024-10-31 | 2024-11-21 |
| Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib - Lung Cancer, Small Cell | Phase 2 | Recruiting | Shanghai Chest Hospital | 52 | 2024-10-13 | 2024-11-21 |
| Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer Trilaciclib Injection [Cosela], Placebo - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2024-07-09 | 2024-08-26 |
| Trilaciclib Prevents Myelosuppression With Chemoradiotherapy Trilaciclib - Myelosuppression | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-06-26 | 2024-09-24 |
| the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib Trilaciclib - Non-small Cell Lung Cancer | Phase 2 | Enrolling by invitation | Henan Cancer Hospital | 41 | 2024-04-02 | 2026-01-28 |
| Myeloprotection With Trilaciclib in Pan-cancer Population Trilaciclib Injection, Paclitaxel, Carboplatin - Non-Small Cell Lung Cancer, Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 132 | 2024-03-01 | 2024-03-07 |
| Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma Trilaciclib - Osteosarcoma | Phase 2 | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 20 | 2024-02-01 | 2024-01-22 |
| Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer Trilaciclib, Pembrolizumab, Gemcitabine - Metastatic Triple-Negative Breast Cancer | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 36 | 2024-01-10 | 2026-08-20 |
| Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy Trilaciclib, Epirubicin, Cyclophosphamide - Breast Neoplasms | Phase 2 | Recruiting | wang shusen | 116 | 2023-09-20 | 2023-11-30 |
| A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC Trilaciclib Injection - NSCLC | Phase 2 | Unknown | Taixing People's Hospital | 30 | 2023-08-10 | 2024-03-25 |
| The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC Trilaciclib plus chemotherapy, Chemotherapy - Breast Neoplasm | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 150 | 2023-07-30 | 2023-07-24 |
| Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC Trilaciclib - Triple Negative Breast Cancer | Phase 2 | Unknown | QIAO LI | 50 | 2023-07-03 | 2025-05-02 |
| Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer Trilaciclib, Carboplatin, Paclitaxel - Advanced Squamous Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Sichuan University | 132 | 2023-07-01 | 2023-06-13 |
| Study of Trilaciclib and Lurbinectidin Trilaciclib, Lurbinectedin - Lung Cancer, Small-cell Lung Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 30 | 2022-10-12 | 2026-09-21 |
Showing 20 of 29. Sign in to see all of them.
Breast Neoplasms (7) · Triple Negative Breast Neoplasms (6) · Small Cell Lung Carcinoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (3) · Squamous Cell Carcinoma of Head and Neck (3) · Lung Neoplasms (2) · Osteosarcoma (2) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Hemangiosarcoma (1) · Neoplasms (1) · Neutropenia (1)
G1 Therapeutics, Inc. (8) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Sun Yat-sen University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Henan Cancer Hospital (1) · Hunan Cancer Hospital (1) · Peking University People's Hospital (1) · QIAO LI (1) · QuantumLeap Healthcare Collaborative (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Chest Hospital (1) · Sichuan University (1) · Taixing People's Hospital (1) · The First Affiliated Hospital of Xiamen University (1)
China (14) · United States (11) · France (3) · Spain (3) · Belgium (2) · Bulgaria (2) · Croatia (2) · Georgia (2) · Hungary (2) · North Macedonia (2) · Serbia (2) · Slovakia (2) · Slovenia (2) · Bosnia and Herzegovina (1) · Estonia (1)
Antoinette Tan, MD (1) · Jared Weiss, MD (1) · Laura Esserman, MD, MBA (1) · Lei Deng, PhD (1) · Qiang Liu, Doc (1) · Qiao Li (1) · Shusen Wang, MD (1) · Xiaolin Ge, PHD (1) · Yongsheng Wang (1)
PMID 34405547, PMID 34408488, PMID 33595690, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 31504118, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33004541, PMID 33123968, PMID 34529000, PMID 34741021, PMID 34777341, PMID 34873975, PMID 35623341, PMID 35842567, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39113428, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41810725, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224
2016 (3), 2017 (1)